Provided by Tiger Trade Technology Pte. Ltd.

Aardvark Therapeutics

6.82
+0.930015.79%
Post-market: 6.820.00000.00%19:30 EDT
Volume:173.69K
Turnover:1.12M
Market Cap:147.97M
PE:-2.13
High:6.90
Open:5.91
Low:5.80
Close:5.89
52wk High:17.94
52wk Low:3.35
Shares:21.70M
Float Shares:11.17M
Volume Ratio:1.18
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2080
EPS(LYR):-0.7400
ROE:-66.02%
ROA:-40.38%
PB:1.98
PE(LYR):-9.22

Loading ...

Aardvark Therapeutics Plans to Unblind Hero and Ole Data to Inform Path Forward Following FDA Clinical Hold

THOMSON REUTERS
·
May 15

Aardvark Therapeutics Inc - FDA Places Full Clinical Hold on Aardvark's Ind for Ard-101

THOMSON REUTERS
·
May 15

Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold

GlobeNewswire
·
May 15

Aardvark Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Aardvark Therapeutics price target lowered to $18 from $20 at BofA

TIPRANKS
·
May 10

Analysts Offer Insights on Healthcare Companies: Aardvark Therapeutics, Inc. (AARD), Prothena (PRTA) and Eli Lilly & Co (LLY)

TIPRANKS
·
May 10

RBC Capital Reaffirms Their Hold Rating on Aardvark Therapeutics, Inc. (AARD)

TIPRANKS
·
May 09

Aardvark Therapeutics reports Q1 EPS (99c), consensus (91c)

TIPRANKS
·
May 08

Aardvark Therapeutics Q1 EPS $(0.99) Misses $(0.90) Estimate

Benzinga Earnings
·
May 07

Aardvark Q1 net loss widens to $21.6 million; R&D expenses rise to $16.6 million

Reuters
·
May 07

Aardvark Therapeutics Inc Q1 Operating Expenses USD 22.464 Million

THOMSON REUTERS
·
May 07

Aardvark Therapeutics Inc Q1 Income From Operations USD -22.464 Million

THOMSON REUTERS
·
May 07

Aardvark Therapeutics Inc Q1 Net Income USD -21.588 Million VS. Ibes Estimate USD -18.3 Million

THOMSON REUTERS
·
May 07

Press Release: Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Dow Jones
·
May 07

U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources

Reuters
·
Mar 25

Aardvark Therapeutics Inc : B. Riley Cuts Target Price to $8 From $32

THOMSON REUTERS
·
Mar 24

B. Riley Adjusts Aardvark Therapeutics Price Target to $8 From $32, Maintains Buy Rating

MT Newswires Live
·
Mar 24

RBC Capital Sticks to Its Hold Rating for Aardvark Therapeutics, Inc. (AARD)

TIPRANKS
·
Mar 24

Aardvark Therapeutics Price Target Maintained With a $9.00/Share by BTIG

Dow Jones
·
Mar 24

Aardvark Therapeutics Establishes $150 Million Equity Program

TIPRANKS
·
Mar 24